Nationwide Utilization Trend of Antiresorptive Agents in Turkiye

• Published in: International dental journal 2024-10, Vol.74, p.S94-S95
• Main Authors: Gültekin, Onur, Bayram, Ferit, Aslan, Beste Tacal, Ulucan, Korkut, Aydin, Volkan, Akkoç, Tunç, Akici, Ahmet
• Format: Article
• Language: English
• ISSN: 0020-6539
• DOI: 10.1016/j.identj.2024.07.858

Medication-related osteonecrosis of the jaw (MRONJ) is a serious complication of antiresorptive therapies used for osteoporosis and cancers. In this study, we aimed to examine nationwide utilization trend of frequently-used antiresorptive drugs (bisphosphonate and denosumab) in Türkiye. We collected outpatient and inpatient drug sales data of biphosphonates (zoledronate, alendronate, ibandronate, risedronate, clodronate, pamidronate) and denosumab between 2019-2023 from IQVIA Turkey. We measured utilization as “defined daily dose/1000 inhabitants” (DID) metric, a standardized consumption unit by the WHO. Normally- and nonnormally-distributed data of annual changes were analyzed through ANOVA and Friedman's ANOVA, respectively. We identified that utilization of biphosphonates increased from 2.8±0.3 DID in 2019 to 3.2±0.4 DID in 2023 (p=.042), with non-significant yearly increments in between. The two most widely used biphosphonates in 2019, ibandronate (44.1%) and alendronate (40.4%), showed a shift in rank in 2023, changing to 40.1% and 47.3%, respectively. Risedronate exhibited a steeper increase from 0.05±0.03 DID in 2019 to 0.30±0.04 DID in 2023 (p